Trial Profile

A Phase 2 Study of Once Weekly Nimacimab Injection, Compared to Placebo Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection in Participants Who Are Overweight or Obese

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Mar 2025 According to a Skye Bioscience media release, Phase 2a dosing extended to 52 weeks to enhance long-term safety, tolerability, and efficacy data
20 Mar 2025 According to a Skye Bioscience media release, Enrollment of 136 patients completed for this study.Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule and interim analysis removed.
14 Mar 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com